BioSpace News Archive

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) wishes to announce the appointment of Baker Tilly WM LLP (“Baker Tilly”) as its auditor

Dr. Jonathan Greenburg, DDS, the preeminent U.S. expert on snoring and sleep apnea, is on a mission to help 90 million people breathe easy and lull them to sleep with a three-part solution

Husband and wife team Rob and Kendra Benson decided to build their very own commercial kitchen to produce popular keto and paleo food product, Fat Fit Go

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the appointment of Robert Richard, Ph.D., to the newly created position of Vice President of Research and Development.

Neural Analytics, Inc., a medical robotics company developing and commercializing technologies to measure and track brain health, announces today the first site initiation and first subjects enrolled into the CODEX Study,

Fluoride contributes to degenerative eye diseases such as cataracts, age related macular degeneration (AMD) and glaucoma, reports DT Waugh in the International Journal of Environmental Research and Public Health (March 2019), reports New York State Coalition Opposed to Fluoridation, Inc. (NYSCOF).

Zyppah® retails for $99.95 and is available on Zyppah.com and Amazon.com.

A NEW drug shown to significantly reduce the risk of cancer recurrence or death in an aggressive form of breast cancer has today been approved for use in Australian patients.

Former Johnson & Johnson President and Private Equity CEO Brings Extensive Experience in Consumer Health and Diabetes

Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy.